Skip to main content
Top
Published in: Diabetologia 1/2007

01-01-2007 | Article

Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes

Authors: L. Sauma, N. Franck, J. F. Paulsson, G. T. Westermark, P. Kjølhede, P. Strålfors, M. Söderström, F. H. Nystrom

Published in: Diabetologia | Issue 1/2007

Login to get access

Abstract

Aims/hypothesis

The amount of visceral fat mass strongly relates to insulin resistance in humans. The transcription factor peroxisome proliferator activated receptor gamma (PPARG) is abundant in adipocytes and regulates genes of importance for insulin sensitivity. Our objective was to study PPARG activity in human visceral and subcutaneous adipocytes and to compare this with the most common model for human disease, the mouse.

Materials and methods

We transfected primary human adipocytes with a plasmid encoding firefly luciferase controlled by PPARG response element (PPRE) from the acyl-CoA-oxidase gene and measured PPRE activity by emission of light.

Results

We found that PPRE activity was 6.6-fold higher (median) in adipocytes from subcutaneous than from omental fat from the same subjects (n = 23). The activity was also 6.2-fold higher in subcutaneous than in intra-abdominal fat cells when we used a PPARG ligand-binding domain-GAL4 fusion protein as reporter, demonstrating that the difference in PPRE activity was due to different levels of activity of the PPARG receptor in the two fat depots. Stimulation with 5 μmol/l rosiglitazone did not induce a PPRE activity in visceral adipocytes that was as high as basal levels in subcutaneous adipocytes. Interestingly, in mice of two different strains the PPRE activity was similar in visceral and subcutaneous fat cells.

Conclusions/interpretation

We found considerably lower PPARG activity in visceral than in subcutaneous primary human adipocytes. Further studies of the molecular mechanisms behind this difference could lead to development of drugs that target the adverse effects of visceral obesity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Evans DJ, Murray R, Kissebah AH (1984) Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. J Clin Invest 74:1515–1525PubMedCrossRef Evans DJ, Murray R, Kissebah AH (1984) Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. J Clin Invest 74:1515–1525PubMedCrossRef
2.
go back to reference Ohlson LO, Larsson B, Svardsudd K et al (1985) The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34:1055–1058PubMed Ohlson LO, Larsson B, Svardsudd K et al (1985) The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34:1055–1058PubMed
3.
go back to reference Kim SK, Kim HJ, Hur KY et al (2004) Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr 79:593–599PubMed Kim SK, Kim HJ, Hur KY et al (2004) Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr 79:593–599PubMed
4.
go back to reference Goodpaster BH, Krishnaswami S, Resnick H et al (2003) Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 26:372–379PubMed Goodpaster BH, Krishnaswami S, Resnick H et al (2003) Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 26:372–379PubMed
5.
go back to reference Empana JP, Ducimetiere P, Charles MA, Jouven X (2004) Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation 110:2781–2785PubMedCrossRef Empana JP, Ducimetiere P, Charles MA, Jouven X (2004) Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation 110:2781–2785PubMedCrossRef
6.
go back to reference Kortelainen ML, Sarkioja T (2001) Visceral fat and coronary pathology in male adolescents. Int J Obes Relat Metab Disord 25:228–232PubMedCrossRef Kortelainen ML, Sarkioja T (2001) Visceral fat and coronary pathology in male adolescents. Int J Obes Relat Metab Disord 25:228–232PubMedCrossRef
7.
go back to reference Rebuffe-Scrive M, Andersson B, Olbe L, Bjorntorp P (1989) Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 38:453–458PubMedCrossRef Rebuffe-Scrive M, Andersson B, Olbe L, Bjorntorp P (1989) Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 38:453–458PubMedCrossRef
8.
go back to reference Zierath JR, Livingston JN, Thorne A et al (1998) Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 41:1343–1354PubMedCrossRef Zierath JR, Livingston JN, Thorne A et al (1998) Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 41:1343–1354PubMedCrossRef
9.
go back to reference Klein S, Fontana L, Young VL et al (2004) Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 350:2549–2557PubMedCrossRef Klein S, Fontana L, Young VL et al (2004) Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 350:2549–2557PubMedCrossRef
10.
go back to reference Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P (2002) A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 26:193–199PubMedCrossRef Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P (2002) A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 26:193–199PubMedCrossRef
11.
go back to reference Arner P (2003) The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137–145PubMedCrossRef Arner P (2003) The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137–145PubMedCrossRef
12.
go back to reference Lee CH, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201–2207PubMedCrossRef Lee CH, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201–2207PubMedCrossRef
13.
go back to reference Savage DB, Tan GD, Acerini CL et al (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52:910–917PubMed Savage DB, Tan GD, Acerini CL et al (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52:910–917PubMed
14.
go back to reference Barroso I, Gurnell M, Crowley VE et al (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883PubMed Barroso I, Gurnell M, Crowley VE et al (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883PubMed
15.
go back to reference Loinder K, Soderstrom M (2004) Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR). J Steroid Biochem Mol Biol 91:191–196PubMedCrossRef Loinder K, Soderstrom M (2004) Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR). J Steroid Biochem Mol Biol 91:191–196PubMedCrossRef
16.
go back to reference Stenkula KG, Said L, Karlsson M et al (2004) Expression of a mutant IRS inhibits metabolic and mitogenic signalling of insulin in human adipocytes. Mol Cell Endocrinol 221:1–8PubMedCrossRef Stenkula KG, Said L, Karlsson M et al (2004) Expression of a mutant IRS inhibits metabolic and mitogenic signalling of insulin in human adipocytes. Mol Cell Endocrinol 221:1–8PubMedCrossRef
17.
go back to reference Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P (2000) Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6:998–1007PubMed Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P (2000) Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6:998–1007PubMed
18.
go back to reference DiRenzo J, Soderstrom M, Kurokawa R et al (1997) Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 17:2166–2176PubMed DiRenzo J, Soderstrom M, Kurokawa R et al (1997) Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 17:2166–2176PubMed
19.
go back to reference Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109:2054–2057PubMedCrossRef Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109:2054–2057PubMedCrossRef
20.
go back to reference Sauma L, Stenkula KG, Kjolhede P, Strålfors P, Soderstrom M, Nystrom FH (2006) PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 22:60–68PubMedCrossRef Sauma L, Stenkula KG, Kjolhede P, Strålfors P, Soderstrom M, Nystrom FH (2006) PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 22:60–68PubMedCrossRef
21.
go back to reference Montague CT, Prins JB, Sanders L et al (1998) Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384–1391PubMed Montague CT, Prins JB, Sanders L et al (1998) Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384–1391PubMed
22.
go back to reference Armoni M, Kritz N, Harel C et al (2003) Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 278:30614–30623PubMedCrossRef Armoni M, Kritz N, Harel C et al (2003) Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 278:30614–30623PubMedCrossRef
23.
go back to reference Westergren H, Danielsson A, Nystrom FH, Strålfors P (2005) Glucose transport is equally sensitive to insulin stimulation, but basal and insulin-stimulated transport is higher, in human omental compared with subcutaneous adipocytes. Metabolism 54:781–785PubMedCrossRef Westergren H, Danielsson A, Nystrom FH, Strålfors P (2005) Glucose transport is equally sensitive to insulin stimulation, but basal and insulin-stimulated transport is higher, in human omental compared with subcutaneous adipocytes. Metabolism 54:781–785PubMedCrossRef
24.
go back to reference Emery EM, Schmid TL, Kahn HS, Filozof PP (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 7:342–353PubMed Emery EM, Schmid TL, Kahn HS, Filozof PP (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 7:342–353PubMed
Metadata
Title
Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes
Authors
L. Sauma
N. Franck
J. F. Paulsson
G. T. Westermark
P. Kjølhede
P. Strålfors
M. Söderström
F. H. Nystrom
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0515-x

Other articles of this Issue 1/2007

Diabetologia 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine